π₯ ποΈ CONFERENCE COVERAGE: Inflammatory skin diseases don't always stop at the skin.
π Read the session recap: hubs.li/Q04F-zGw0
#DermNexus2026 #DermatologyTimes #NPPAConnect #InflammatorySkinDisease
1
288
π΅π₯ DAY 1 RECAP: That's a wrap on the first day of #DermNexus2026!
Missed a session or want to revisit the highlights? We've rounded up the key takeaways from day 1 in Scottsdale!
hubs.li/Q04F-j660
#DermNexus2026 #DermatologyTimes #NPPAConnect
π₯ CONFERENCE COVERAGE: Emerging therapeutic targets are taking center stage at #DermNexus2026!
π Catch up on the latest insights from Scottsdale: hubs.li/Q04FZjxH0
#DermNexus #DermatologyTimes #NPPAConnect #Dermatology
301
Nail detachment: 39% of GLP-1 receptor agonist users vs 9% of matched controls. More from EADV 2026 β
hubs.li/Q04FCp690
292
π₯ ποΈ CONFERENCE COVERAGE: From new treatment targets to emerging therapies, dermatology's therapeutic landscape is evolving rapidly!
π Read our session recap: hubs.li/Q04FYlcJ0
#DermatologyTimes #DermNexus #Dermatology #AdvancedPracticeProviders
199
CONFERENCE COVERAGE ποΈ: What's on the agenda at DermNexus 2026? π¬
π hubs.li/Q04FXfFC0
#DermNexus2026 #DermatologyTimes #InflammatorySkinDisease #DermatologyEducation
234
π€ DERMNEXUS 2026 IS UNDERWAY!
Lauren Miller, conference chair, officially welcomes attendees to DermNexus 2026 in Scottsdale, Arizona, kicking off the first session of the meeting!
#DermNexus2026 #DermatologyTimes #Dermatology #AdvancedPracticeProviders
217
EADV 2026 in review: the research and therapeutic advances that defined the congress β
hubs.li/Q04FCnbP0
1
269
Lisa Swanson, MD, returns to Donβt Be Rash to discuss newer nonsteroidal topical treatments and how they may fit into care for pediatric patients in this episode, supported by Arcutis.
Β
Watch here: hubs.li/Q04FBk3x0
Β
#PediatricPsoriasis #DontBeRash
185
βοΈβ³ THE PRACTICE BRIEF: From updated iPLEDGE requirements to proposed Medicare payment cuts, recent developments are creating new considerations for dermatology practices.
hubs.li/Q04FJFVx0
#ThePracticeBrief #DermatologyPractice
264
Zasocitinib tops deucravacitinib. 3 years of nemolizumab. New targets in lupus and HS. EADV 2026, at a glance β
hubs.li/Q04FClwb0
1
411
π₯π¬ Q&A: Skin cancer prevention doesn't end when summer does.
π Read the full Q&A: hubs.li/Q04FJDW30
#SkinCancerPrevention #SunProtection #PatientEducation #Dermatology
190
π‘ EXPERT INSIGHTS: How should clinicians interpret cross-trial efficacy data when selecting treatments for alopecia areata?
π Read more: Weighing Cross-Trial Data and Patient Timelines in Alopecia Areata Treatment
#AlopeciaAreata #JAKInhibitors #HairLoss #Dermatology
2
391
π₯ EXPERT PERSPECTIVES: Could severe atopic dermatitis affect more than just the skin in children?
π Watch now: hubs.li/Q04FJGKF0
#ExpertPerspectives #AtopicDermatitis #PediatricDermatology #Dupilumab
π THE AESTHETIC EDGE: Bioelements and Celluma are joining forces to bring LED light therapy into professional facial treatments.
π Read more: hubs.li/Q04FJB2T0
#AestheticDermatology #LEDLightTherapy #SkinCare #Dermatology
1
341
π‘ EXPERT COMMENTARY: Could a more comprehensive approach to indoor tanning prevention help reduce melanoma risk?
π Read more: hubs.li/Q04FJBRs0
#MelanomaPrevention #SkinCancerAwareness #IndoorTanning #Dermatology
273
Can AI speed up skin cancer pathways? How many viral "glass skin" TikToks get it wrong?
Swipe through EADV 2026 highlights β
hubs.li/Q04FBZn40
1
339
π‘ EXPERT INSIGHTS: Mark G. Lebwohl, MD, discusses anticipated monitoring requirements, the differences between oral and injectable therapies, and how disease severity and patient preferences can guide individualized treatment decisions.
π₯ Watch now: hubs.li/Q04FpLnW0
4
527
π¨ FDA UPDATE: The FDA has implemented updated iPLEDGE REMS requirements for isotretinoin, introducing changes to the program designed to prevent fetal exposure during treatment.
π Read more: hubs.li/Q04FpM3w0
#Isotretinoin #iPLEDGE #FDAUpdate #Dermatology
1
6
1,340
π CLINICAL TRIAL UPDATE: Aclaris Therapeutics' investigational antibody bosakitug failed to meet the primary and secondary efficacy end points in a phase 2 trial for moderate to severe atopic dermatitis.
hubs.li/Q04FpG-b0
#Bosakitug #AclarisTherapeutics
2
519







